article thumbnail

Delivering responsible AI in the healthcare and life sciences industry

IBM Business Partners

With today’s new generative AI products, trust, security and regulatory issues remain top concerns for government healthcare officials and C-suite leaders representing biopharmaceutical companies, health systems, medical device manufacturers and other organizations.

article thumbnail

Strengthening cybersecurity in life sciences with IBM and AWS

IBM Business Partners

Cloud is transforming the way life sciences organizations are doing business. Cloud computing offers the potential to redefine and personalize customer relationships, transform and optimize operations, improve governance and transparency, and expand business agility and capability.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Leveraging generative AI on AWS to transform life sciences

IBM Business Partners

Life sciences industry is beginning to take notice and aims to leapfrog the technological advances. Life sciences industry has—for decades now—moved from the traditional discovery-based drug development to target market-based drug development paradigm. Why IBM Consulting for generative AI on AWS?

article thumbnail

Life Sciences’ Contribution to the US Digital Therapeutics Market to Grow the Fastest amongst all End Users

Frost & Sullivan

As life sciences companies aim to enhance patients’ treatment experiences and find new biomarkers that aid drug discovery, DTx companies diversify their pipelines by adding new indications, addressing unmet needs. “In About Frost & Sullivan. Contact us: Start the discussion. US Digital Therapeutics Growth Opportunities.

article thumbnail

Top 10 Growth Opportunities in the Healthcare & Life Sciences Industry

Frost & Sullivan

31, 2022 – The post COVID-19 pandemic recovery and other geopolitical events in 2021 has left the healthcare & life sciences industry in a remarkable position to be ready for 2022 and beyond. The post Top 10 Growth Opportunities in the Healthcare & Life Sciences Industry appeared first on Frost & Sullivan.

article thumbnail

Life Sciences’ Contribution to the US Digital Therapeutics Market to Grow the Fastest amongst all End Users

Frost & Sullivan

As life sciences companies aim to enhance patients’ treatment experiences and find new biomarkers that aid drug discovery, DTx companies diversify their pipelines by adding new indications, addressing unmet needs. “In About Frost & Sullivan. Contact us: Start the discussion. US Digital Therapeutics Growth Opportunities.

article thumbnail

EY and ServiceNow Deepen Ties to Tackle GenAI Compliance, Governance & Risk

Channel Insider

EY and ServiceNow have expanded their strategic alliance to offer robust solutions for generative AI (GenAI) compliance, governance, and risk management. The challenge many clients face is implementing appropriate governance when adopting the technology.